Your shopping cart is currently empty

Sutetinib is an orally effective tyrosine kinase inhibitor that targets enzymes linked to tumor growth and angiogenesis, such as VEGFR (VEGFR-1/2/3 with Ki= 0.009 µM), PDGFR (PDGFR-α/β with Ki= 0.008 µM), and the proto-oncogene cKIT. It inhibits the proliferation, migration, and tubular structure formation of endothelial and fibroblast cells, demonstrating antitumor activity across various cancer cell lines.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | Sutetinib is an orally effective tyrosine kinase inhibitor that targets enzymes linked to tumor growth and angiogenesis, such as VEGFR (VEGFR-1/2/3 with Ki= 0.009 µM), PDGFR (PDGFR-α/β with Ki= 0.008 µM), and the proto-oncogene cKIT. It inhibits the proliferation, migration, and tubular structure formation of endothelial and fibroblast cells, demonstrating antitumor activity across various cancer cell lines. |
| Molecular Weight | 439.51 |
| Formula | C26H25N5O2 |
| Cas No. | 1259519-20-4 |
| Smiles | N(C=1C2=C(C=C(OCC)C(NC(/C=C/CN(C)C)=O)=C2)N=CC1C#N)C3=CC(C#C)=CC=C3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.